These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 21591514)
1. Clinical application of tumour markers: a review. Amayo AA; Kuria JG East Afr Med J; 2009 Dec; 86(12 Suppl):S76-83. PubMed ID: 21591514 [TBL] [Abstract][Full Text] [Related]
2. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol; 1996 Oct; 14(10):2843-77. PubMed ID: 8874347 [TBL] [Abstract][Full Text] [Related]
3. [Clinical usefulness of circulating tumor markers]. Ohkura H Gan To Kagaku Ryoho; 2004 Jul; 31(7):1131-4. PubMed ID: 15272600 [TBL] [Abstract][Full Text] [Related]
4. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA). Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221 [TBL] [Abstract][Full Text] [Related]
5. Cancers Screening in an Asymptomatic Population by Using Multiple Tumour Markers. Wang HY; Hsieh CH; Wen CN; Wen YH; Chen CH; Lu JJ PLoS One; 2016; 11(6):e0158285. PubMed ID: 27355357 [TBL] [Abstract][Full Text] [Related]
6. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Sturgeon CM; Duffy MJ; Stenman UH; Lilja H; Brünner N; Chan DW; Babaian R; Bast RC; Dowell B; Esteva FJ; Haglund C; Harbeck N; Hayes DF; Holten-Andersen M; Klee GG; Lamerz R; Looijenga LH; Molina R; Nielsen HJ; Rittenhouse H; Semjonow A; Shih IeM; Sibley P; Sölétormos G; Stephan C; Sokoll L; Hoffman BR; Diamandis EP; Clin Chem; 2008 Dec; 54(12):e11-79. PubMed ID: 19042984 [TBL] [Abstract][Full Text] [Related]
7. RATIONAL USE OF SERUM TUMOUR MARKERS IN DIAGNOSTICS AND TREATMENT OF SOLID TUMOURS. Plavetić ND; Gnjidić M; Kulić A; Ivić M; Kukec I; Vidović M Lijec Vjesn; 2016; 138(3-4):85-92. PubMed ID: 30146854 [TBL] [Abstract][Full Text] [Related]
9. [Clinical relevance of tumor markers]. Lamerz R Wien Klin Wochenschr; 1989 Jul; 101(14):464-72. PubMed ID: 2672606 [TBL] [Abstract][Full Text] [Related]
10. Comparing the diagnostic accuracy of five common tumour biomarkers and CA19-9 for pancreatic cancer: a protocol for a network meta-analysis of diagnostic test accuracy. Ge L; Pan B; Song F; Ma J; Zeraatkar D; Zhou J; Tian J BMJ Open; 2017 Dec; 7(12):e018175. PubMed ID: 29282264 [TBL] [Abstract][Full Text] [Related]
11. Evidence for the clinical use of tumour markers. Duffy MJ Ann Clin Biochem; 2004 Sep; 41(Pt 5):370-7. PubMed ID: 15333188 [TBL] [Abstract][Full Text] [Related]
12. Tumour markers and their utility in imaging of abdominal and pelvic malignancies. Lahoud RM; O'Shea A; El-Mouhayyar C; Atre ID; Eurboonyanun K; Harisinghani M Clin Radiol; 2021 Feb; 76(2):99-107. PubMed ID: 32861463 [TBL] [Abstract][Full Text] [Related]
13. Influence of cardiopulmonary resuscitation on levels of tumour markers. Berent R; Auer J; Porodko M; Lamm G; Weber T; Wimmer E; Seier J; Aspöck G; Eber B Eur J Cancer Care (Engl); 2006 Jul; 15(3):252-6. PubMed ID: 16882121 [TBL] [Abstract][Full Text] [Related]
14. Prevalence of abnormal levels of serum tumour markers in elderly people. Lopez LA; Del Villar V; Ulla M; Fernandez F; Fernandez LA; Santos I; Rabadan L; Gutierrez M Age Ageing; 1996 Jan; 25(1):45-50. PubMed ID: 8670528 [TBL] [Abstract][Full Text] [Related]
15. [Standards, Options and Recommendations (SOR) for tumor markers in breast cancer. SOR Working Group]. Basuyau JP; Blanc-Vincent MP; Bidart JM; Daver A; Deneux L; Eche N; Gory-Delabaere G; Pichon MF; Riedinger JM Bull Cancer; 2000 Oct; 87(10):723-37. PubMed ID: 11084536 [TBL] [Abstract][Full Text] [Related]
16. Tumour markers in internal medicine: a low-cost test or an unnecessary expense? A retrospective study based on appropriateness. Arioli D; Pipino M; Boldrini E; Amateis E; Cristani A; Ventura P; Romagnoli E; De Santis MC; Zeneroli ML Intern Emerg Med; 2007 Jun; 2(2):88-94. PubMed ID: 17622496 [TBL] [Abstract][Full Text] [Related]
17. CEA, CA 242, CA 19-9, CA 72-4 and hCGbeta in the diagnosis of recurrent colorectal cancer. Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Järvinen H; Haglund C Tumour Biol; 2004; 25(5-6):228-34. PubMed ID: 15627885 [TBL] [Abstract][Full Text] [Related]